Skip to content
Screener

Artiva Biotherapeutics, Inc. ARTV Q2 2026 earnings

Reported August 6, 2026 · After market close

EPS-$0.63Miss by $0.00
EPS estimate-$0.63

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full
Operating income-$26.9M-17.9%
Net income-$25.0M-17.6%
EPS (diluted)-$0.63+27.6%

Balance sheet

See full
Cash & equivalents$301.9M+944%
Total debt$9.8M-25.5%
Total equity$347.5M+133%
Total assets$368.6M+118%

Cash flow

See full
Operating cash flow-$20.4M+11.4%
CapEx$415.0K-60.7%
Free cash flow-$20.8M+13.6%

Valuation & ratios

Valuation

as of 08/10/26
See full
Market cap$550.99M+783%
Enterprise value$258.93M+455%

Returns & leverage

See full
Return on equity-36.6%—
Debt / equity0×-0.1×
Current ratio24.2×+10.3×

FAQ

When did Artiva Biotherapeutics, Inc. report Q2 2026 earnings?
Artiva Biotherapeutics, Inc. (ARTV) reported Q2 2026 earnings on August 6, 2026 after market close.
What were Artiva Biotherapeutics, Inc.'s Q2 2026 revenue and EPS?
Artiva Biotherapeutics, Inc. reported eps of $-0.63 for Q2 2026.
Did Artiva Biotherapeutics, Inc. beat estimates in Q2 2026?
EPS missed the consensus estimate of $-0.63 by $0.00.
How did Artiva Biotherapeutics, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 27.6% from $-0.87.
Where can I find Artiva Biotherapeutics, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-337986) and the 10-Q periodic report (0001193125-26-338029) directly on SEC EDGAR. The filing index links above go to sec.gov.